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Abstract
Human immunodeficiency virus (HIV) infection frequently causes neurologic disease even with anti-retroviral treatment.
Although associations between MHC class I alleles and acquired immunodeficiency syndrome (AIDS) have been reported,
the role MHC class I alleles play in restricting development of HIV-induced organ-specific diseases, including neurologic
disease, has not been characterized. This study examined the relationship between expression of the MHC class I allele
Mane-A*10 and development of lentiviral-induced central nervous system (CNS) disease using a well-characterized simian
immunodeficiency (SIV)/pigtailed macaque model. The risk of developing CNS disease (SIV encephalitis) was 2.5 times
higher for animals that did not express the MHC class I allele Mane-A*10 (P=0.002; RR=2.5). Animals expressing the Mane-
A*10 allele had significantly lower amounts of activated macrophages, SIV RNA, and neuronal dysfunction in the CNS than
Mane-A*10 negative animals (P,0.001). Mane-A*10 positive animals with the highest CNS viral burdens contained SIV gag
escape mutants at the Mane-A*10-restricted KP9 epitope in the CNS whereas wild type KP9 sequences dominated in the
brain of Mane-A*10 negative animals with comparable CNS viral burdens. These concordant findings demonstrate that
particular MHC class I alleles play major neuroprotective roles in lentiviral-induced CNS disease.
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Introduction
With 33 million people infected with HIV (UNAIDS 2007),
unraveling the pathogenesis of this infection is critical. In addition
to immunosuppression manifest as AIDS, HIV infection frequent-
ly causes neurologic disease ranging from subtle cognitive deficits
to overt dementia, often occurring despite anti-retroviral treatment
[1,2]. The neuropathogenesis of HIV infection remains incom-
pletely understood.
MHC class I-restricted CD8
+ T cell responses are a critical part
of the adaptive cell-mediated immune response to HIV-1 infection
of humans and SIV infection of macaques [3,4]. The HLA-B*27
and HLA-B*5701 MHC class I alleles have been associated with
slower progression to AIDS with maintenance of CD4
+ T cell
counts [5–7]. Similarly, the presence of the MHC class I alleles
Mane-A*10 in pigtailed macaques and Mamu-A*01 in rhesus
macaques have been linked to slower progression to AIDS
following SIV infection [8–11]. Despite these provocative
relationships between MHC class I alleles and development of
the syndrome AIDS, associations between MHC class I alleles and
HIV-induced organ-specific disease outcomes including HIV-
associated neurocognitive disorders have not been identified.
CD8
+ T cells are present in high numbers in the brain of HIV-
infected patients during asymptomatic infection, supporting the
concept that effective cytotoxic T cell control of HIV/SIV in the
CNS may be crucial to prevent lentiviral CNS disease [12,13].
To facilitate pathogenesis studies, we have established an
accelerated SIV/macaque model of HIV-induced CNS disease. In
this model, pigtailed macaques (Macaca nemestrina) are inoculated
simultaneously with a cloned neurovirulent virus, SIV/17E-Fr,
and an immunosuppressive swarm, SIV/DeltaB670. Using this
dual infection protocol, the majority of infected animals develop
prototypic SIV encephalitis by three months post-infection that
closely resembles HIV encephalitis [14].
The provocative finding that some SIV-infected pigtailed
macaques do not develop CNS disease (although all animals
develop similar high levels of persistent viremia and progress to
AIDS) suggests that there are host genetic factors that confer
resistance to lentiviral-induced CNS disease. To determine
whether MHC class I allele expression patterns could explain
the variable progression to SIV-induced CNS disease, we
established which MHC class I alleles were expressed by 63
pigtailed macaques and then compared MHC class I allele
expression with CNS disease outcome following SIV infection.
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Animals
This retrospective cohort study included 63 pig-tailed macaques
(Macaca nemestrina) that were intravenously inoculated with SIV/
DeltaB670 (50 AID50), and SIV/17E-Fr (10,000 AID50). Treat-
ment of SIV-infected pigtailed macaques included: IFNb (1.3 ug/
kg every 3 days; n=6), minocycline (2 mg/kg twice daily; n=14),
9-[(R)-2-phosphonylmethoxy) propyl] adenine (PMPA; 30mg/kg
once daily; n=5), or PMPA with minocycline (n=6)[15]. Animals
were perfused with sterile saline at euthanasia to remove blood
and circulating virus from brain. The animal procedures in this
study were performed according to the principles set forth by the
Institutional Animal Care and Use Committee at Johns Hopkins
University and the National Research Council’s Guide for the care
and use of laboratory animals.
Immunohistochemical staining and histopathology
Primary antibody against CD68 (KP-1, diluted 1:2,000, DAKO,
Carpinteria, CA), a marker of microglial activation and macrophage
infiltration, was used to immunostain brain sections. To identify b-
A P Pa c c u m u l a t i o ni na x o n s ,c o r o n a ls e c t i o n so fb r a i nt i s s u ei n c l u d i n g
basal ganglia, frontal cortex, and corpus callosum, were immunohis-
tochemically stained with the monoclonal antibody anti-b-amyloid
precursor protein 695 (Clone LN27, Zymed, South San Francisco,
CA). All brain tissue sections were stained by an automated
immunostainer (Optimax Plus, BioGenex, San Ramon, CA) for
uniformity. Streck-fixed, paraffin-embedded brain tissue sections
were deparaffinized, rehydrated, and then post-fixed in Streck tissue
fixative (Streck Laboratories, Omaha, NE) for 20 minutes. After
rinsing in water, tissues were heated in a microwave in sodium citrate
buffer (0.01M, pH 6.0) for 8 minutes to retrieve antigen. Endogenous
peroxidase was quenched with 3% H2O2 for 10 minutes and then
sections were blocked with buffered casein for 10 minutes. Primary
a n t i b o d yw a sa p p l i e dt ot i s s u es e c t i o n sf o r6 0m i n u t e sa tr o o m
temperature, the tissues were washed in buffer, and then secondary
biotinylated multilink antibody (Biogenex, San Ramon, CA) was
added for 20 minutes. After washing, streptavidin-horseradish
peroxidase was applied for 20 minutes, followed by diaminobenzi-
dene tetrahydrochloride in buffer containing H2O2 for 10 minutes.
Sections were then washed, dehydrated and mounted [16,17].
Quantitative image analysis
To standardize sampling from animal to animal, coronal brain
tissue sections from all animals were prepared from the same
location in the basal ganglia, 5 mm posterior to the head of the
caudate nucleus. For each animal, twenty adjacent fields in the
corpus callosum from sections immunostained for APP were
captured at 2006 magnification (an area of 2.8 mm
2) using a
Sensys 2 digital camera (Photometrics, Tucson, AZ) then analyzed
by IP Lab imaging software (Scanalytics, Vienna, VA). Image
analysis transects of the corpus callosum started on the midline
and proceeded laterally, encompassing the identical region of
corpus callosum in all animals. Similarly, twenty 2006fields were
captured in subcortical white matter subjacent to cingulate gyrus
for measurement of CD68 representing macrophage/microglial
activation (Figure 1). Images were binarized and the total area
occupied by immunopositive pixels calculated to measure the total
area of immunostaining [16,17].
Measuring SIV RNA by real-time RT-PCR
Viral RNA was quantitated in the basal ganglia of brain by real-
time PCR using primers in the SIV gag region on an Applied
Biosystems Prism 5700 Sequence Detection System. The primers to
detect unspliced viral RNA included (SGAG03–59-C A G G G AA I I
AAG CAG ATG AAT TAg–39: SGAG04–59- GTTTCACTTT-
CTCTTCTGCGT g–39 and pSUS05–59 (FAM)ATTTGGATTA-
GCAGAAAGCCTGTTGGAG (TAMRA+BLOCKED)–39) [18].
Reference-strand mediated conformational analysis
Pigtail macaque class I sequences spanning 200 bp of the
polymorphic peptide binding regions were amplified using Phusion
DNA polymerase (Finnzymes, Espoo, Finland) using 1 mlo fa
25 mM phosphate-labelled forward primer (59Phos-shtRSCA; 59-
[phos]-AggggCCggAgTATTggg-39) and an unlabelled reverse
primer (39sht-RCSA; 59-TTCAggRCgAWgTAATCC-39), for an
initial30 s98uCstep followedby35cyclesof98uC5 s,55uC1s,and
72uC 20 s, then a final extension at 72uC 5 minutes. Reference
strands were amplified under the same conditions, but with a FAM-
labeled forward primer (59FAM-shtRSCA; 59[6-FAM]-AggggCCg-
gAgTATTggg-39) and a phosphate-labelled reverse primer (39Phos-
shtRSCA; 59-[phos]-TTCAggRCgAWgTAATCC-39). Following
amplification, samples were digested for 30 minutes at 37uC with
10 U lambda exonuclease (NE Biolabs, Ipswich, MA, USA). The
single-stranded cDNA amplicons were then heteroduplexed with
the fluorescently labelled reference strand in a reaction involving
4 minutes at 95uC, 5 minutes at 55uC, and 15 minutes at 15uC.
The labelled heteroduplexes were run on a non-denaturing gel
(LongRanger gel mix, Cambrex, Mt. Waverly, VIC, Australia) on
an ABI PRISM 377 DNA Sequencer (Applied Biosystems, Foster
Figure 1. SIV infection induced encephalitis, increased CNS CD68 expression, and axonal accumulation of APP. SIV-infected pig-tailed
macaques that developed encephalitis had multifocal perivascular accumulations of infiltrating macrophages and multinucleate giant cells (A, arrows
denote giant cells, * denotes blood vessel lumen, hematoxylin and eosin stain, bar=50 uM), increased CNS CD68 expression reflecting activation of
macrophages and microglia in subcortical white matter shown by immunohistochemical staining with an anti-CD68 antibody (B, bar=50 uM), and
accumulation of APP in axons (arrows) in the corpus callosum (C, bar=100 uM).
doi:10.1371/journal.pone.0003603.g001
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mobility. The pattern of heteroduplexes from each reaction were
then compared to the mobilities of previously characterized,
sequence-verified Mane MHC class I clones using DAx data
acquisition and analysis software (Van Mierlo Software, Eindhoven,
the Netherlands) [9,19].
Sequence-specific PCR for Mane-A*10 expression
RNA was isolated from pre-inoculation PBMCs and cDNA was
generated. Initial PCR was performed for Sequence Specific
Primer (SSP) 2 (forward 59-CGG GTC TCA CAC CTT CCA
GAG GAT GTA T-39 reverse 59-CGG TCC AGG AAC GCA
GGT CCC-39) and GAPDH (forward 59-TGC CAT CAA TGA
CCC CTT CAT TGA CCT C-39 reverse 59-CCC AGC CTT
CTC CAT GGT GGT GAA GAC-39) under the following cycling
conditions: 95uC 20 min followed by 35 cycles 94uC 20 sec, 72uC
40 sec final extension 72uC 10 min. Any samples with a 134 bp
amplified product were subsequently run for SSP1 (forward 59-
GGC CAA CAC ACA GAC CTA CCG AGA GAG-39 reverse
59-CCC TGC CGT CGT AGG CGT ACT GGC TAT AT-39
161 bp) and SSP3 (forward 59-GGC GCC TCC TCC GCG GAT
ATA G-39 reverse 59-GGC ACT CGC CCT CCA CGT AGG T-
39 174 bp) in addition to SSP2 and GAPDH repeat. Samples
which were negative for SSP2 were repeated to verify their Mane-
A*10 status while samples positive for SSP2, SSP1, and SSP3 were
considered Mane-A*10 positive.
Cloning and sequencing of the SIV KP9 gag epitope
PCR was performed on cDNA prepared from inoculum viral
stock RNA or RNA extracted from the basal ganglia using the SIV
gag KP9-specific primers forward 59-CAC GCA GAA GAG AAA
GTG AA-39 and reverse 59-GTT CCT CGA AT(AG) TC(GT)
GAT CC-39 using Platinum PCR supermix (Invitrogen, Carlsbad,
CA) and the following cycle conditions: 94uC for 2 min., 30 cycles
at 94uC for 15 sec, 56uC for 30 sec, and 72uC for 1 min., followed
by a final extension of 72uC for 8 min [20]. The bulk PCR
product was then cloned into pCRII vector using the TOPO TA
cloning kit (Invitrogen). Colonies were plated on LB Kanamycin
with X-gal and grown overnight. Colonies were selected and
grown in LB Kan 10% glycerol for 12 h statically and sequenced
by Agencourt Biosciences (Beverly, MA). Sequences were aligned
and analyzed using Geneious 3.0.3 software.
Statistical Methods
Comparisons of biomarkers (e.g., CD68, APP, CNS SIV RNA
level) between groups (Mane-A*10 allele present versus Mane-A*10
allele absent) utilized Student’s two sample t-test. A log 10
transformation of CD68, APP, and CNS SIV RNA measurements
was performed before the use of the t-test to ensure the data were
more normally distributed than in original scale (Figure 2). In
addition, t-tests were performed at each day post-inoculation to
identify differences, if any, between the Mane-A*10 groups for
those biomarkers measured over time (Figure 3). Risk ratios and
Fisher’s exact test were conducted to identify the magnitude and
significance, if any, of the association of Mane-A*10 allele
expression and SIV CNS disease (Table 1). In addition, to
evaluate the possible influence of treatment on this association, the
Mantel-Haenzel homogeneity of risk ratios test was conducted
across the treatment strata-specific risk ratios. The null assumption
of this test is that treatment does not modify the effect measure of
the Mane-A*10 and SIV CNS disease association whereby one
could then combine the frequencies across the strata (when
P.0.05). Risk ratios are presented for this study because the
design was a retrospective (historic) cohort study, which means the
animals were included in this study based on their exposure status
(Mane-A*10), as opposed to their disease status (SIV CNS disease),
and followed per study protocol to determination of disease status.
Results and Discussion
In this study, a well-characterized SIV/pigtailed macaque
model of HIV CNS disease was examined to determine whether
expression of the MHC class I allele Mane-A*10 influenced SIV
CNS disease outcome [14,16,17,21]. 24 of 63 (38%) pigtailed
macaques included in this study expressed the Mane-A*10 allele as
determined by reference strand-mediated conformational analysis
and/or sequence-specific PCR performed as reported previously
[19]. SIV encephalitis, with multifocal perivascular and paren-
chymal accumulations of SIV-infected macrophages and multinu-
cleate giant cells (Figure 1A), was identified in 32 of 63 macaques
infected with both SIV/17E-Fr and SIV Delta/B670 by
Figure 2. Reduced CNS macrophage activation, SIV replication, and axonal APP accumulation associated with Mane-A*10
expression. Mane-A*10 expression was associated with reduced CNS inflammation, SIV replication and neuronal damage in SIV-infected macaques.
A) SIV-infected macaques expressing the Mane-A*10 allele (circles) had significantly lower CNS macrophage infiltration and activation than animals
without the allele (triangles, P=0.001) shown by measuring the amount of CD68 immunostaining in subcortical white matter of the brain. B) Animals
expressing the Mane-A*10 allele (circles) also had significantly lower SIV RNA in the basal ganglia of the brain than animals without the allele
(triangles, P,0.001). SIV RNA was measured by real time RT-PCR. C) Animals expressing the Mane-A*10 allele (circles) also had significantly lower
axonal accumulation of APP in the corpus callosum than animals without the allele (triangles, P,0.001,) demonstrating that expression of Mane-A*10
is neuroprotective. Solid (black) symbols represent the SIV-infected animals that developed SIV encephalitis whereas the open symbols indicate
animals that were SIV-infected but did not develop SIV encephalitis.
doi:10.1371/journal.pone.0003603.g002
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macaques with encephalitis typically have concordant increases in
CNS immunostaining for the macrophage activation marker
CD68 (Figure 1B) and increases in accumulation of amyloid
precursor protein (APP) in axons reflecting neuronal dysfunction
(Figure 1C).
Only six of 24 (25%) SIV-infected pigtailed macaques
expressing the Mane-A*10 allele developed SIV CNS disease
whereas 26 of 39 (67%) SIV-infected animals lacking the Mane-
A*10 allele developed SIV CNS disease (Table 1). Therefore,
macaques not expressing the Mane-A*10 allele were 2.5 times as
likely to develop SIV CNS disease than macaques expressing the
Mane-A*10 allele, demonstrating that expression of Mane-A*10 is
neuroprotective in SIV-infected pigtailed macaques (P=0.002,
Fisher’s exact test; risk ratio RR=2.5). Mane-A*10 positive animals
also had lower amounts of CNS immunostaining for CD68
(reflecting decreased SIV-induced activation of both infiltrating
macrophages and resident microglia in the brain) than Mane-A*10
negative animals (Figure 2A; P=0.001) consistent with the
reduced incidence of SIV encephalitis in animals with the Mane-
A*10 allele. The presence of macrophages and microglia in the
brain of HIV-infected individuals has been highly correlated with
the severity of HIV-induced dementia [22].
We subsequently examined whether SIV-infected pigtailed
macaques expressing the Mane-A*10 allele had altered levels of
viral replication in the CNS versus animals without the allele by
measuring SIV RNA in the basal ganglia via real time RT-PCR.
Macaques with the Mane-A*10 allele had significantly lower levels
of SIV RNA in the basal ganglia of the brain versus animals
without the Mane-A*10 allele (Figure 2B; P,0.001).
We then measured accumulation of amyloid precursor protein
(APP) in the corpus callosum of SIV-infected macaques as a
marker of neuronal dysfunction to verify that expression of the
Mane-A*10 allele also conferred protection against neuronal
damage [16]. Animals with the Mane-A*10 allele had significantly
lower amounts of APP (measured by immunostaining and digital
image analysis) than animals that did not express the allele
(Figure 2C, P,0.001). Although we did not measure behavioral
deficits in all of the SIV-infected animals in this study, we
previously have demonstrated that the amount of both APP
accumulation and CD68 immunostaining are strongly correlated
with impaired fine-motor control in this SIV/macaque model,
suggesting that animals expressing the Mane-A*10 allele also may
be protected against behavioral impairment caused by SIV [23].
The concordant findings of decreased incidence of SIV
encephalitis, lower macrophage activation, markedly reduced
CNS viral load, and decreased APP accumulation in axons in
pigtailed macaques positive for the Mane-A*10 allele strongly
suggest that particular MHC class I alleles, such as Mane-A*10,
play major neuroprotective roles in lentiviral-induced CNS
Figure 3. Mane-A*10 expression did not influence CD4+ T cell decline or plasma viral load but was associated with lower CSF viral
loads. Comparing longitudinal trends in CD4+ T cell decline from baseline pre-infection values and plasma SIV RNA demonstrated that Mane-A*10
expression was not associated with either extent of CD4+ T cell decline throughout infection (A) or with altered plasma viral load set points in
untreated SIV-infected macaques at any time point from primary through asymptomatic to terminal stages of (B). To determine whether Mane-A*10
expression was associated with altered viral replication in the periphery, mean plasma viral load throughout infection was measured in untreated SIV-
infected animals grouped by Mane-A*10 status (Mane-A*10 positive animals represented by circles, n=11; Mane-A*10 negative animals represented
by triangles, n=21). Plasma viral load also did not differ significantly between these groups at any time-point from day 14 post-inoculation until
terminal sampling (P.0.05). Similarly, Mane-A*10 expression status was not associated with extent of % CD4+ T cell decline in SIV-infected macaques,
with no statistically significant difference between groups of animals composed of Mane-A*10 positive animals (circles) versus Mane-A*10 negative
macaques (triangles). Combined, these data indicate that neither plasma viral load or CD4+ T cell loss are associated with expression of Mane-A*10 in
pigtailed macaques inoculated with SIV/17E-Fr and SIV/DeltaB670. In contrast, mean SIV RNA levels in CSF were lower in the group of Mane-A*10
positive animals (circles) versus Mane-A*10 negative macaques (triangles).
doi:10.1371/journal.pone.0003603.g003
Table 1. Mane-A*10 Status versus Development of SIV Encephalitis.
Untreated Treated
Mane-A*10 allele SIV CNS Disease No SIV CNS Disease SIV CNS Disease No SIV CNS Disease
Absent 17 4 9 9
Present 4 7 2 11
Strata Specific Risk Ratio (P-value) 2.2 (0.020) 3.3 (0.066)
Combined Risk Ratio (P-value) 2.5 (0.002)*
The Mantel-Haenzel test of homogeneity (
*) failed to reject the hypothesis that the strata specific risk ratios were equal (P=0.632).
doi:10.1371/journal.pone.0003603.t001
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T cell counts from pre-inoculation values to terminal time-points
was not associated with Mane-A*10 status (Figure 3A), the
protective effects of Mane-A*10 conferring resistance to SIV-
induced CNS disease appear to be independent of its influence on
AIDS progression in this SIV/macaque model. Furthermore, in
this study, pigtailed macaques expressing Mane-A*10 inoculated
simultaneously with both SIV/DeltaB670 and SIV/17E-Fr did
not have significantly lower plasma viral loads at any time point
post-infection than animals not expressing Mane-A*10 (Figure 3B),
even though CNS SIV RNA levels were markedly lower in Mane-
A*10 positive animals. Combined, these findings demonstrate that
the expression of Mane-A*10 in this SIV model is specifically
associated with improved CNS disease outcome and is not simply
a reflection of slower progression to AIDS or lowered viral
replication in the periphery. This is consistent with our previous
finding that plasma viral load does not predict SIV-induced CNS
disease in this SIV/macaque model [17]. In contrast with plasma
viral load, CSF viral load was lower in SIV-infected macaques
expressing the Mane-A*10 allele (Figure 3C) reflecting lowered
CNS viral replication after day 14 post-inoculation in animals
expressing Mane-A*10. The difference in CSF vRNA was
significantly lower at day 42 in the group expressing Mane-A*10
(P=0.029) versus the group without Mane-A*10. It is likely that the
groups were not significantly different at later time points because
1) viral escape developed in some of the Mane-A*10 positive
animals and 2) the CSF does not solely represent CNS viral
replication but also reflects SIV replication in other compartments
including meninges and blood.
The lack of a reduction in peripheral (i.e. plasma) viral load in the
Mane-A*10 positive pigtailed macaques inoculated intravenously with
SIV/DeltaB670 and SIV/17E-Fr in this report is in distinction to our
previous work that evaluated 8 animals (of which 3 were Mane-A*10
positive) infected with SIV/mac251 intrarectally. Several factors
likely account for this difference including different viruses that were
used for inoculation, inoculation route, inoculation dose, and host
genetic factors in addition to Mane-A*10. Furthermore, peripheral
immune escape in some animals may play a role in abrogating any
Mane-A*10-related affect on peripheral viral load. We previously
showed that Mane-A*10 positive animals infected with SIV/mac251
that undergo immune escape at KP9 have viral loads that resemble
those of Mane-A*10 negative macaques [9].
32 of the 63 SIV-infected animals examined in this study did not
receive treatment during infection; the other 31 SIV-infected
pigtailed macaques received IFNb, minocycline, 9-[(R)-2-phos-
phonylmethoxy) propyl] adenine (PMPA), or PMPA with
minocycline (as detailed in Materials and Methods). To examine
the possibility that the Mane-A*10 and SIV CNS disease
association was modified by treatment during SIV infection, the
relative risks were calculated separately for SIV-infected macaques
that either did or did not receive treatment (Table 1). The strata-
specific risk ratio for the group of untreated SIV-infected
macaques was 2.2 (P=0.02, Fisher’s exact) and the relative risk
for the treated group of SIV-infected macaques was 3.3 (P=0.066,
Fisher’s exact). A significant difference in risk of SIV CNS disease
versus expression of Mane-A*10 was not found between treated
and untreated groups of SIV-infected macaques indicating that the
Mane-A*10 expression was neuroprotective even in treated SIV-
infected animals (Mantel-Haenzel test of homogeneity; P=0.632).
Thus, it is likely that MHC class I alleles exert a similar
neuroprotective effect in HIV-infected individuals irrespective of
treatment status.
In pigtailed macaques, Mane-A*10 allele restriction of the
immunodominant SIV Gag epitope KP9 has been associated with
lowered plasma viral loads after intra-rectal SIVmac251 inocula-
tion [8,9]. Conversely, escape mutations in the SIV KP9 Gag
epitope are present at high frequency in Mane-A*10 positive
animals with high plasma viral loads. In this study, to determine
whether viral escape at the immunodominant SIV Gag KP9
epitope could be detected in the CNS of animals with the Mane-
A*10 allele that developed SIV CNS disease with high levels of
vRNA in brain, cDNA samples prepared from brain RNA from
the six Mane-A*10 positive animals with SIV encephalitis were
bulk PCR amplified and sequenced. SIV gag sequences also were
determined for six Mane-A*10 negative macaques with comparable
levels of SIV RNA in the CNS and for the viral stocks of SIV/
DeltaB670 and SIV/17E-Fr used to inoculate macaques
(Figure 2B and Table 2). The four Mane-A*10 positive animals
(animals 18292, PVg2, A4P012, and A2P005) with the highest
CNS viral burdens contained gag escape mutants (K165R) in the
CNS. In contrast, wild type KP9 sequences strongly dominated in
the brain of Mane-A*10 negative animals (Table 2). This
difference illustrates that viral escape mutations are present in
the CNS and may be playing a pivotal role in the development of
lentiviral-induced encephalitis.
Future studies to evaluate the longitudinal evolution of escape
mutants in the CNS versus plasma would determine whether
selection pressure on SIV Gag varies between these distinct
compartments and whether Gag escape mutants could arise in the
CNS independently from the periphery and then traffic from the
brain to seed the periphery. Our previous studies comparing SIV
genotypes in the CNS versus plasma have suggested that latent
Table 2. Viral Escape in the CNS of Mane-A*10 Animals with
SIV Encephalitis.
Inoculum Gag 164-172 Frequency
SIV/17E-Fr KKFGAEVVP 100%
SIV/DeltaB670 --------- 100%
Mane-A*10 positive CNS SIV RNA
(Copy eq/ug RNA)
18292 4.2610
7 -R------- 100% (10/10)
PVg2 9.9610
6 --------- 33% (16/48)
PVg2 -R------- 67% (32/48)
A4P012 4.6610
6 --------- 90% (9/10)
A4P012 -R------- 10% (1/10)
A2P005 1.4610
5 -R------- 100% (12/12)
T4363 3.5610
4 --------- 100% (42/42)
DM19 1.2610
3 --------- 100% (11/11)
Mane-A*10 negative
A4P028 1.2610
8 --------- 100% -
PNw1 6.8610
7 --------- 100% -
A1P014 3.4610
7 --------- 100% -
A1P005 2.9610
7 --------- 100% (11/11)
CC33 1.1610
6 --------- 100% (12/12)
BM03 2.0610
5 --------- 100% (12/12)
The four Mane-A
*10 positive animals (animals 18292, PVg2, A4P012, and
A2P005) with the highest CNS viral burdens contained high levels of gag escape
mutants (K165R) in the CNS. In contrast, wild type KP9 sequences strongly
dominated in the brain of Mane-A
*10 negative animals. Wild type KP9
sequences also were exclusively detected in viral stocks of SIV/DeltaB670 and
SIV/17E-Fr used for inoculation.
doi:10.1371/journal.pone.0003603.t002
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replicate in the periphery [24].
SIV/macaque models are widely used to define the pathogen-
esis of HIV infection and for development of effective preventive
strategies. Identifying the MHC class I alleles that influence SIV
disease progression is crucial for refining our understanding of
SIV/macaque models especially because macaque studies fre-
quently employ relatively small numbers of animals. As this study
illustrates, the impact of MHC class I alleles on SIV disease
progression can extend beyond influencing the time course of
AIDS onset or plasma viral load set point. In fact, MHC class I
allele effects may be strongest in modifying organ-specific diseases
induced by HIV independent of any appreciable effects in the
periphery. The distinct neuroprotective influence of Mane-A*10 on
SIV-induced CNS disease also demonstrates that the relative
efficacy of cell-mediated control of pathogens in the CNS can be a
distinct process from cell-mediated immune control in the
periphery. Some SIV/macaque models used to study HIV CNS
disease have relied on antibody-mediated depletion of CD8+ T
cells to increase the incidence of CNS disease. This strategy may
compromise pathogenesis studies in the SIV/macaque model
because 1) cell-mediated immune responses are eliminated that
play crucial roles in controlling viral replication in the CNS of
HIV-infected individuals and 2) CD8+ T cell depletion decreases
immune mediated selection pressure on viral evolution in the
CNS. Additional, as yet unidentified, MHC I and II alleles and
polymorphisms within genes across extended MHC haplotypes are
also likely to influence CNS disease and other organ-specific
diseases[25].
This study shows that MHC class I-restricted CTL responses
against SIV Gag play a major role in preventing lentiviral-induced
CNS disease. Strategies aimed at stimulating MHC class I-
restricted CD8 T cell responses against immunodominant HIV
epitopes may be of great value to prevent as well as treat HIV
CNS disease. The identification of a neuroprotective MHC class I
allele in this SIV/macaque model sets the stage for performing
parallel studies in neuroAIDS cohorts to determine whether
particular MHC class I alleles may protect HIV-infected
individuals from HIV-associated neurologic disorders.
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